

4. The RNA ligand of claim 3 wherein said ligand is substantially homologous to and has substantially the same ability to bind VEGF as a ligand selected from the group consisting of the sequences set forth in Tables 1-4 (SEQ ID NOS: 10-86).

5. The RNA ligand of claim 3 wherein said ligand has substantially the same structure and substantially the same ability to bind VEGF as a ligand selected from the group consisting of the sequences set forth in Tables 1-4 (SEQ ID NOS: 10-86).

6. The RNA ligand to VEGF of claim 1 identified according to the method comprising:

a) contacting a Candidate Mixture of RNA with VEGF, wherein the RNA having an increased affinity to VEGF relative to the Candidate Mixture may be partitioned from the remainder of the Candidate Mixture;

b) partitioning the increased affinity RNA from the remainder of the Candidate Mixture; and

c) amplifying the increased affinity RNA to yield a mixture of RNA enriched for RNA having an increased affinity for VEGF; whereby RNA Ligands of VEGF are identified.

7. The RNA ligand to VEGF of claim 3 identified according to the method comprising:

a) contacting a Candidate Mixture of RNA with VEGF, wherein the RNA having an increased affinity to VEGF relative to the Candidate Mixture may be partitioned from the remainder of the Candidate Mixture;

b) partitioning the increased affinity RNA from the remainder of the Candidate Mixture; and

c) amplifying the increased affinity RNA to yield a mixture of RNA enriched for RNA having an increased affinity for VEGF; whereby RNA Ligands of VEGF are identified.

8. A Complex comprised of the RNA ligand to VEGF of claim 1 and a Non-Immunogenic, High Molecular Weight Compound.

9. The Complex of Claim 8 further comprising a Linker between said ligand and said Non-Immunogenic, High Molecular Weight Compound.


10. The Complex of Claim 8 wherein said Non-Immunogenic, High Molecular Weight Compound is a Polyalkylene Glycol.

11. The Complex of claim 10 wherein said Polyalkylene Glycol is polyethylene glycol.

12. The Complex of claim 11 wherein said polyethylene glycol has a molecular weight of about between 10-80 K.

13. The Complex of claim 11 wherein said polyethylene glycol has a molecular weight of about between 20-45 K.


14. The Complex of claim 11 wherein said Complex is



Ligand Component =

fCmGmGrArAfUfCmAmGfUmGmAmAfUmGfCfUfUmAfUmAfCmAfUfCfCmG-3'3'-dT  
(VEGF ligand)

15. The Complex of claim 11 wherein said Complex is



Ligand Component =

fCmGmGrArAfUfCmAmGfUmGmAmAfUmGfCfUfUmAfUmAfCmAfUfCfCmG-3'3'-dT  
(VEGF ligand)

16. The method of claim 2 wherein said Non-Immunogenic, High Molecular Weight Compound is a Polyalkylene Glycol.

17. The method of claim 16 wherein said Polyalkylene Glycol is polyethylene glycol.

18. The method of claim 17 wherein said polyethylene glycol has a molecular weight of about between 10-80 K.

19. The method of claim 17 wherein said polyethylene glycol has a molecular weight of about 20-45 K.